Research programme: miniaturised sustained release therapeutics - EyePoint Pharmaceuticals

Drug Profile

Research programme: miniaturised sustained release therapeutics - EyePoint Pharmaceuticals

Alternative Names: TBD; Tethadur™ - EyePoint Pharmaceuticals

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator pSivida
  • Developer EyePoint Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Glaucoma; Retinitis pigmentosa

Most Recent Events

  • 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Ophthalmic, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Glaucoma in USA (Ophthalmic, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top